TY - JOUR
T1 - Utility of multiphase contrast enhancement patterns on CEH-EUS for the differential diagnosis of IPMN-derived and conventional pancreatic cancer
AU - Yashika, Jun
AU - Ohno, Eizaburo
AU - Ishikawa, Takuya
AU - Iida, Tadashi
AU - Suzuki, Hirotaka
AU - Uetsuki, Kota
AU - Yamada, Kenta
AU - Yoshikawa, Masakatsu
AU - Gibo, Noriaki
AU - Shimoyama, Yoshie
AU - Ishikawa, Eri
AU - Furukawa, Kazuhiro
AU - Nakamura, Masanao
AU - Honda, Takashi
AU - Ishigami, Masatoshi
AU - Hirooka, Yoshiki
AU - Kawashima, Hiroki
AU - Fujishiro, Mitsuhiro
N1 - Publisher Copyright:
© 2021 IAP and EPC
PY - 2021/3
Y1 - 2021/3
N2 - Background: Intraductal papillary mucinous neoplasm (IPMN) is reported as a high-risk factor for pancreatic cancer (PC) that includes IPMN-derived cancers (IPMC) and the development of invasive pancreatic ductal adenocarcinoma (PDAC) concomitant with IPMN. Since invasive IPMC and PDAC exhibit different oncological behaviors, their differentiation is clinically important. We aimed to investigate the use of contrast-enhanced harmonic endoscopic ultrasound (CEH-EUS) for the differential diagnosis between invasive IPMC and PDAC. Methods: This study involved 183 consecutive patients with PC (invasive IPMC: 42, PDAC concomitant with IPMN: 9, without IPMN: 132) who underwent CEH-EUS preoperatively. While investigating the patterns, enhanced effects in the solid part of the tumor were compared with those in the surrounding pancreatic parenchyma after administration of Sonazoid® and evaluated as hyperenhanced, isoenhanced, or hypoenhanced. We retrospectively compared the enhanced pattern of CEH-EUS by using multiphasic analysis and clinicopathological factors between invasive IPMC and PDAC. Results: In multiphase evaluations at 20, 40 and 60 s in CEH-EUS, 75.2% (106/141) of PDACs were hypoenhanced (−) at ≥2 of the 3 time points, with significant differences from those of invasive IPMC (P < 0.001). The solid tumor diameter was significantly larger in PDAC than in invasive IPMC, and the tumor stage and preoperative serum carbohydrate antigen 19-9 level were higher. After propensity score matching of stage and solid tumor diameter, contrast enhancement patterns were significantly more persistent in invasive IPMC than in PDAC (P = 0.0013). Conclusions: Multiphase evaluation using CEH-EUS is a useful method for differentiating between invasive IPMC and PDAC.
AB - Background: Intraductal papillary mucinous neoplasm (IPMN) is reported as a high-risk factor for pancreatic cancer (PC) that includes IPMN-derived cancers (IPMC) and the development of invasive pancreatic ductal adenocarcinoma (PDAC) concomitant with IPMN. Since invasive IPMC and PDAC exhibit different oncological behaviors, their differentiation is clinically important. We aimed to investigate the use of contrast-enhanced harmonic endoscopic ultrasound (CEH-EUS) for the differential diagnosis between invasive IPMC and PDAC. Methods: This study involved 183 consecutive patients with PC (invasive IPMC: 42, PDAC concomitant with IPMN: 9, without IPMN: 132) who underwent CEH-EUS preoperatively. While investigating the patterns, enhanced effects in the solid part of the tumor were compared with those in the surrounding pancreatic parenchyma after administration of Sonazoid® and evaluated as hyperenhanced, isoenhanced, or hypoenhanced. We retrospectively compared the enhanced pattern of CEH-EUS by using multiphasic analysis and clinicopathological factors between invasive IPMC and PDAC. Results: In multiphase evaluations at 20, 40 and 60 s in CEH-EUS, 75.2% (106/141) of PDACs were hypoenhanced (−) at ≥2 of the 3 time points, with significant differences from those of invasive IPMC (P < 0.001). The solid tumor diameter was significantly larger in PDAC than in invasive IPMC, and the tumor stage and preoperative serum carbohydrate antigen 19-9 level were higher. After propensity score matching of stage and solid tumor diameter, contrast enhancement patterns were significantly more persistent in invasive IPMC than in PDAC (P = 0.0013). Conclusions: Multiphase evaluation using CEH-EUS is a useful method for differentiating between invasive IPMC and PDAC.
UR - http://www.scopus.com/inward/record.url?scp=85099694485&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099694485&partnerID=8YFLogxK
U2 - 10.1016/j.pan.2020.12.022
DO - 10.1016/j.pan.2020.12.022
M3 - Article
C2 - 33487577
AN - SCOPUS:85099694485
SN - 1424-3903
VL - 21
SP - 390
EP - 396
JO - Pancreatology
JF - Pancreatology
IS - 2
ER -